Breaking Finance News

A statement released earlier today by RBC Capital Markets about Enanta Pharmaceuticals Inc (NDAQ:ENTA) bumps the target price to $58.00

Boasting a price of $45.53, Enanta Pharmaceuticals Inc (NDAQ:ENTA) traded 1.60% higher on the day. With the last close up 28.71% from the two hundred day average, compared with the S&P 500 Index which has increased 0.01% over the date range. Enanta Pharmaceuticals Inc has recorded a 50-day average of $45.64 and a two hundred day average of $37.42. Volume of trade was down over the average, with 123,020 shares of ENTA changing hands under the typical 173,786

RBC Capital Markets bumped up the target of Enanta Pharmaceuticals Inc (NDAQ:ENTA) to $58.00 stating a potential upside of 0.27%.

On 9/15/2017, RBC Capital Markets released a statement on Enanta Pharmaceuticals Inc (NDAQ:ENTA) bumped up the target price from $0.00 to $54.00 that suggested an upside of 0.20%.

Performance Chart

Enanta Pharmaceuticals Inc (NDAQ:ENTA)

With a total market value of $0, Enanta Pharmaceuticals Inc has with a one year low of $22.17 and a one year high of $49.50 .

More About Enanta Pharmaceuticals Inc (NDAQ:ENTA)

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *